| Literature DB >> 18721821 |
Dong-Wan Seo1, Soo Hyeon Kim, Seok-Hyun Eom, Hyun Jae Yoon, Young-Rak Cho, Pyeung-Hyeun Kim, Yong Kee Kim, Jeung-Whan Han, Tere Diaz, Bei-Yang Wei, William G Stetler-Stevenson.
Abstract
We have previously reported that tissue inhibitor of metalloproteinases-2 (TIMP-2), an endogenous inhibitor of matrix metalloproteinase, modulates angiogenic responses through the MMP inhibition-independent activity. In this study, we investigate the molecular mechanisms of TIMP-2-mediated growth inhibition in response to fibroblast growth factor-2 (FGF-2). Pre-treatment with a protein tyrosine phosphatase inhibitor orthovanadate or expression of a dominant negative Shp-1 mutant fails to induce TIMP-2 inactivation of FGF-2 signaling pathways in human microvascular endothelial cells. We also show that TIMP-2 inhibition of FGF-2-induced p42/44(MAPK) activation and cell proliferation is associated with TIMP-2 binding to integrin alpha3beta1 on endothelial cell surfaces, as demonstrated by use of anti-integrin alpha3 or beta1 blocking antibodies, or disruption of integrin alpha3 expression by siRNA. Collectively, our results indicate that TIMP-2 inhibits FGF-2 signaling pathways through association with integrin alpha3beta1 and Shp-1-dependent inhibition of p42/44(MAPK) signaling, which in turn, results in suppression of FGF-2-stimulated endothelial cell mitogenesis.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18721821 PMCID: PMC2574962 DOI: 10.1016/j.mvr.2008.07.003
Source DB: PubMed Journal: Microvasc Res ISSN: 0026-2862 Impact factor: 3.514